Corporate
Servier
Worldwide
Healthcare
Professionals
Servier
Medical Art
Career
Opportunities
Patient
Information
Goals
Key figures
Product portfolio
Research & Development
Human resources
Videos
News library
Servier R&D
Research Centers
The Fruits of Research
Servier in Diabetes
The major steps...
Cardiovascular diseases
Diabetes
ENT
Neurosciences
Osteoporosis
Venous disease
Cardiovascular resources
Coversyl
Hyperium
Natrilix SR
Preterax
Procoralan
Vastarel MR
Diabetes resources
Diamicron MR
ENT resources
Locabiotal
Neurosciences resources
Stablon
Trivastal Retard
Duxil
Osteoporosis resources
Osteoscoop
Protelos
Venous disease resources
Daflon 500
Powerpoint image bank
Preview all slide kits
Powerpoint templates
Suggestions
E-mail alert
User's guide
Joining Servier
Job opportunities
Application
Cardiovascular
Diabetes
Venous Disease
Atheroma
Coronary Artery Disease
The Heart
Heart Failure
Hypertension
Risk Factors
Stroke
Diabetes
Venous Insufficiency
Home
Index
Search
Contact
Site map
Home
>
Index
Index
Synomia Search
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Abdominal pain
Absence of data
ACE inhibition
ACE inhibitor
Action in Diabetes and in Vascular Disease
Acute hemorrhoidal attacks
Additional benefits
Additional efficacy
ADVANCE study
AI (augmentation index)
Aim of this study
Allergic reactions
Angina patients
Angiotensin-converting enzyme
Angiotensin II antagonists
Angiotensin II receptor antagonists
Animal studies
Antianginal agents
Antianginal efficacy
Appearance of reflux
Arterial stiffness
ASCOT
ASCOT study
ASCOT trial
ATC code
Attached References
B
Baseline characteristics
BDNF (brain-derived neurotrophic factor)
BEAUTIFUL study
Beta blockers
Blood pressure
Blood pressure reduction
Blood pressure regulation
BMD (bone mineral density)
Bone formation
Bone mineral density
Bone resorption
Bone turnover in favor of formation
BP (blood pressure)
Brain neuroplasticity
Brain stem
C
CAD (coronary artery disease)
CAFstudy
Capillary hyperpermeability
Capillary resistance
Cardiac energy metabolism
Cardiac Outcomes
Cardiac remodeling
Cardiovascular benefits
Cardiovascular outcome
Cardiovascular protection
Central blood pressure
Central hemodynamics
Cerebral aging
Cerebrovascular accidents
Cerebrovascular disease
Cessation of treatment
Chronic heart failure
Chronic treatment
Chronic venous disease
CIVIQ questionnaire
Clin Drug
Clinical outcomes
Clinical vertebral fractures
Cognitive function
Collaborative Group
Combination with MAOIs
Concomitant use
Congestive heart failure
Conventional therapy
Coronary artery disease
Coversyl
Creatinine clearance
D
DAFLON 500 mg
Daily practice
Department of Cardiology
Depressed patients
Depressive episodes
Diabetic hypertensives
Diastolic dysfunction
Diosmin
Diuretic antihypertensive
Divided doses
Dosage adjustment
Double-blind placebo-controlled study
Drug interactions
Dual antibiotic
Dual mode of action
Duxil
E
Effective treatment
Effect of PRETERAX
Effects of a blood pressure
Efficacy in hypertensive patients
Efficacy of ivabradine
Efficacy of PRETERAX on hypertrophy in patients
Elderly patients
Energy metabolism
Enzyme inhibitor
Enzyme inhibitors
EUROPA
EUROPA study
EURopean trial On reduction with Perindopril
Event rates
Evidence of heart failure
Excellent efficacy
Excellent tolerance
Experimental studies
F
Fading of effect
Fatty acid
Fatty acid oxidation
Femoral neck
FFA (free fatty acid)
First antiosteoporotic treatment
Flavonoid fraction
Fusafungine
G
Gastrointestinal disorders
Gliclazide
Glucose oxidation
Granules for oral suspension
H
Healthy subjects
Healthy volunteers
Heart failure
Heart failure patients
Heart rate reduction
Hemodynamic agents
Hemorrhoidal attacks
Hemorrhoidal disease
Hepatic impairment
High affinity
Hip fractures
HR (heart rate)
Hydrophilic matrix
Hyperium
Hyperium's mode of action
Hypersensitivity reactions
Hypersensitivity syndromes
HYpertension in the Very Elderly Trial
Hypertensive patients
Hypertensive patients with LVH
I
Imidazoline receptors
Improved outcomes
Improvement in symptoms
Incorporated company of SERVIER
Indapamide
Inflammatory efficacy
Inflammatory process
Inhibitor therapy
Innovative formulation
Innovative mode of action
International recognition
Ischemic cardiomyopathy
Ischemic heart failure
Ischemic myocardium
Ivabradine
L
Lack of data
Largest morbidity mortality trial
Left ventricular systolic dysfunction
Leg edema
LIVE study
Locabiotal
Long-acting ACE inhibitor
Long-term safety
Low-dose combination
Lower heart rate
LRN (lateral reticular nucleus)
Lumbar spine
LVH (left ventricular hypertrophy)
Lymphatic drainage
M
Magnetic Resonance Imaging
Medicinal products
Micronized flavonoids
Micronized form
Micronized purified flavonoid fraction
MI (myocardial infarction)
Modified-release formulation
Mood disorders
MR (modified release)
N
NATRILIX SR
Natrilix SR at a glance
NATRILIX SR treatment
Neurosensory tissue
New clinical vertebral fractures
New study focus
New vertebral fracture
Nonmicronized diosmin
Nonvertebral fractures
Normalization rate
O
Older regimen
Oral administration
Oral tetracycline
Ordinary diosmins
Oxygen availability
P
Parallel-group study
Parkinson's disease
Patients aged
Patients's quality of life
Patients with coronary heart disease
Patients with hepatic impairment
Patients with left ventricular dysfunction
Patients with renal failure
PEP-CHF
Perindopril-
Pharmacodynamic properties
Pharmacological properties
Phase III studies
Phlebotropic drugs
Piribedil
Placebo-controlled study
Placebo-controlled trial
Plasma levels
Postmenopausal osteoporosis
Postmenopausal women with osteoporosis
Post MI patients
Powerful antihypertensive efficacy
PREAMI
PREAMI (Perindopril Remodelling in Elderly with Acute Myocardial Infarction)
Preserved ejection fraction
Preserved LV function
PRETERAX
PRETERAX strategy
Pre-treatment
Prevalent fracture
Product description
Product overview
PROGRESS
Progression of chronic venous disease
Progression of disease
Proofs of efficacy
PROTELOS
PROTELOS's mode of action
PROTELOS treatment
Publications in hypertension
Publications of interest
Pure heart rate
Pure heart rate reduction
R
Ranelate
Rate reduction
Rebalances bone turnover
Recommended dosage
Recommended dose
Recurrent stroke
Red cells
Reference antihypertensive
Regression of LVH
RELIEF study
Renal insufficiency
Resting heart rate
Rilmenidine
Risk of hip fractures
Risk of new vertebral fracture
Runny nose
S
Sequential monotherapy
SERVIER
Severe renal failure
Sexual disturbances
Skin rash
SOTI
SOTI (Spinal Osteoporosis Therapeutic Intervention)
SOTI study
P
blocker therapy
S
Stable angina
Stable coronary artery disease
STABLON
Stage of disease
Standard therapy
Strontium ranelate
Study population
Study show
Superior clinical efficacy
Superior efficacy
Sympathetic outflow
Sympathetic overactivity
Symptomatic treatment
Symptoms of chronic venous disease
Systemic antibiotics
T
Taccardi AA
Target organs
Teratogenic effects
Therapeutic doses
Throat infections
Tianeptine
Transient ischaemic attack
Treatment of angina pectoris
Treatment of hemorrhoids
Treatment of postmenopausal osteoporosis
Treatment of venous disease
Treatment with PROTELOS
Trimetazidine
Trimetazidine modified release
Trivastal
TROPOS
TROPOS study
U
Unique composition
Unique local treatment
Unique properties
V
Vascular events
Vascular outcomes
Venous hypertension
Ventricular dysfunction
Ventricular function
Ventricular systolic dysfunction
Vertebral fracture
W
Worldwide results of the RELIEF study
© 2008 LES LABORATOIRES SERVIER,
an incorporated company of SERVIER
All Rights Reserved -
Terms of Use
Last updated: 08/04/2008
SERVIER does not sell its products over the Internet -
More information